Barely Significant
← all excerpts

Killing SCLC: insights into how to target a shapeshifting tumor.

Genes Dev · 2022 · PMC8973850 · PMID 35318269

1
hedged sentence
closest p
boldest claim

The sentences

showed a trendno p-value reported
Moreover, SCLC-P tumors showed a trend for OS benefit in the combination ICB arm (EP + Atezo 9.6 mo vs.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.